title: Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in             patients with chronic hepatitis B.
abstract: The impact of adefovir dipivoxil (ADV) treatment on the immune system in patients with chronic hepatitis B (CHB) is unknown. The present study was designed to determine the expression of six cytokines, IL-2, IFN-γ, TNF-α, IL-4, IL-6 and IL-10, and their correlation with liver functions and clinical responses to ADV treatment. A total of 22 CHB patients were treated with ADV at a daily oral dose of 10 mg. Six cytokines, as well as AST, ALT and HBV DNA levels in blood samples were quantified prior to and following the treatment. A total of 10 healthy volunteers were enrolled as the control group. The six cytokines in CHB patients were significantly lower than in healthy individuals, and were increased significantly following 4, 12 and 24 weeks of ADV treatment. Although ALT, AST and HBV DNA were reduced following treatment, no correlation was found between these six cytokines and liver function or HBV DNA levels. The levels of the six cytokines in the group of patients with a complete clinical response were significantly higher than those in the group with a partial clinical response. ADV treatment increases the immunity of Th1/Th2 cells in CHB patients, and the increases in cytokines partly reflect the efficacy of the antiviral treatment.
authors: Department of Gastroenterology, The First Hospital of Jilin University, Changchun 130021, PR China.
authors: Rong-Li
authors: RL
authors: Piao
authors: Yuan-Yuan
authors: YY
authors: Liu
authors: Dan
authors: D
authors: Tian
authors: Zhen-Hua
authors: ZH
authors: Ma
authors: Manli
authors: M
authors: Zhang
authors: Chong
authors: C
authors: Zhao
authors: Jun-Qi
authors: JQ
authors: Niu
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000284:Administration, Oral; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D016207:Cytokines / Q000097:blood*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism*; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism*; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; D004279:DNA, Viral; D063065:Organophosphonates; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000225:Adenine; C106812:adefovir dipivoxil